SAVAYSA®

Drug Information Related Patent

Hold Company

DAIICHI SANKYO INC

Learn More

Dosage and Administration

TABLET;ORAL

Specification

EQ 15MG BASE; EQ 30MG BASE; EQ 60MG BASE

Indication

SAVAYSA® is suitable for reducing nonvalvular atrial fibrillation caused the risk of stroke and systemic embolism. It can also be used for the treatment of deep vein thrombosis and pulmonary embolism.

Use

Instructions for Use

API

EDOXABAN TOSYLATE

API Structure

We Supply

EDOXABAN TOSYLATE

Note:

In-house Standard
Facility GMP
USMF/China DMF/DMF/CDE

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
7365205	2027/4/18
9149532	2028/3/28

API Patent

Patent No	Expiration Date
7365205	2027/4/18

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION